Citotóxicos y terapias diana en Fase III incluyendo
paciente con CP escamoso
Regimen
Squamous
NSCLC only
Line
Planned
N
Primary
endpoint
Clinical trial
registry
Newer cytotoxic agents
1
Nab-P as maintenance
after nab-P + CP vs BSC
Y
Maintenance
540
PFS
NCT02027428
Nab-P + CP Q3W vs Q4W
(elderly)
a
N
1st
280
Safety
NCT02151149
Nedaplatin + D vs CSP + D
Y
1st
488
PFS
NCT02643407
Targeted therapies
1
Custirsen (clusterin
a
) / docetaxel vs
docetaxel
N
2nd
700
OS
NCT01630733
BSC, best supportive care; CP, carboplatin; CSP, cisplatin; D, docetaxel;
nab-P, albumin-bound paclitaxel; NSCLC, non-small cell lung cancer; OS, overall survival; P, paclitaxel;
PARP, polyadenosine diphosphate (ADP)–ribose polymerase; PFS, progression-free survival
1. ClinicalTrials.gov
a
Phase IV study
